FEDERICA CAMPANA

Dr. FEDERICA CAMPANA


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
MCMaria Costantino
Maria Costantino
VGValentina Giudice
Valentina Giudice
FCFEDERICA CAMPANA
FEDERICA CAMPANA
AIAlessandra Anna Iannelli
Alessandra Anna Iannelli
PSPasqualina Scala
Pasqualina Scala
AFAmelia Filippelli
Amelia Filippelli
Background/Objectives: Antibiotic resistance is a growing global threat that significantly impacts public health and healthcare costs. The Italian National Action Plan on Antimicrobial Resistance (PNCAR) was introduced in 2017 to address this issue by improving antibiotic stewardship. This study aimed to evaluate the effectiveness of the PNCAR in enhancing antibiotic management practices in a hospital in southern Italy before and after its implementation. Methods: We conducted an observational monocentric study to analyze antibiotic consumption in a hospital setting before and after the COVID-19 pandemic (2019 and 2023) and to examine prescription appropriateness and the types of used antibiotics. Results: After PNCAR introduction, we recorded a significant increase in antibiotic prescription appropriateness and in Access antibiotic and targeted therapy usage, while Reserve antibiotics were prescribed in ~10% of the cases, with an increasing trend in 2023. Conclusions: Our study supports the importance of targeted stewardship initiatives, including continuous monitoring and education, to sustain antibiotic prescription appropriateness and to reduce antimicrobial resistance.

6 August 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
MCMaria Costantino
Maria Costantino
MMMariagrazia Bathilde Marongiu
Mariagrazia Bathilde Marongiu
MCMaria Grazia Corbo
Maria Grazia Corbo
ACAnna Maria Della Corte
Anna Maria Della Corte
AFAnna Rita Frascogna
Anna Rita Frascogna
FCFrancesco De Caro
Francesco De Caro
Background: RSV remains a leading cause of infant hospitalization worldwide, and the recently approved nirsevimab could represent an effective and safe prophylactic strategy to prevent severe infections in the general neonatal population. Objectives: We conducted a retrospective observational monocentric pilot study in a mixed preterm/term birth cohort to add real-world evidence of the efficacy and safety of nirsevimab in preventing severe RSV infection. Methods: We included a total of 2035 consecutive infants admitted to the Neonatal Unit, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Salerno, Italy, from November 2024 to April 2025. We evaluated 30-day safety profiles and season-wide RSV infection rates, and the outcomes were also compared to newborns’ birth rate in the two previous seasons (2022–2023 and 2023–2024). Results: After the introduction of nirsevimab, a lower RSV infection rate was reported compared to previous seasons, and no adverse effects were observed. Compared to previous seasons, the clinical outcomes were more favorable, as only one unvaccinated neonate with RSV infection required invasive ventilation. Conclusions: In this real-world analysis, we demonstrated a good short-term safety profile of nirsevimab, as well as a potentially high efficacy in the general neonatal population with lower RSV infection incidence. However, future studies are needed to better assess its long-term safety and season-wide efficacy.